clinical-microbiology-biotechnology-2019-keynote

3 / 3

allied
academies
June 12-13, 2019 | Edinburgh, Scotland
8th European Clinical Microbiology and Immunology Congress
&
3rd World congress on Biotechnology
Page 12
Notes:
Microbiology: Current Research | Volume: 3 | ISSN: 2591-8036
Joint Event
Charles H Williams
The Williams Research Laboratory, USA
Malignant hyperthermia - a genetic disease of sodium channel function
Malignant hyperthermia is inherited as a dominant
gene in pigs and in humans. It is characterized by
a rapidly increasing body temperature up to 118 oF with
a metabolic rate over 10x normal, an intense peripheral
vasoconstriction with blood pressures over 400 mmHg and
a fatal outcome in most cases.
TheMH syndrome is triggered by exercise, hauling tomarket,
breeding activity, hot weather and other stress factors. In
humans, the cases are triggered by depolarizing muscle
relaxants, halothane anesthesia and other halogenated
anesthesia compounds. Non-depolarizing muscle relaxants
such as pancuronium and vecuronium are safer to use.
Organon 9426 (rocuronium) is safe to use and provides carry
over protection against the development of MH.
The widespread use of sevoflurane in humans has reduced
the incidence of MH to 1:550,000. Only two cases of MH
have been reported in the USA during the past 30 years.
The MH susceptible pig is an outstanding animal model for
research purposes and has enabled the development of
new muscle relaxants and anesthesia agents that are safer
for human use.
The sodium channels in MH susceptible animals are leaky
and allow the influx of sodium into muscle cells which must
be pumped out by sodium-potassium ATPase, thereby
using ATP and generating heat.
Speaker Biography
Charles H Williams completed his PhD in 1968 and then a post-doctoral at
the Institute for Enzyme Research with David E Green on mitochondrial
studies. He moved to Missouri as an associate professor of biochemistry
and as an assistant professor of medicine. He relocated to TTUHSC-El
Paso in 1982, where MH research was his primary area of interest. He has
published over 50 papers in refereed journals and has presented posters
and lectures at many international events. He has also awarded with US
Patent #5,030,633 in July 9, 1991 for the use of androstane derivative
against malignant hyperthermia. He (editor and author or co-author on
7 of 14 Chapters) has published over 50 manuscripts, published abstracts,
presentations at various meetings and two books published, one of those
books is experimental malignant hyperthermia, New York, Springer Verlag,
1988.
e:
Charles H Williams, Microbiol Curr Res, Volume 3
ISSN: 2591-8036